📊 EOLS Key Takeaways
Is EOLS a Good Investment? Thesis Analysis
Evolus is a financially distressed pharmaceutical company with negative stockholders' equity of -$23.1M, indicating liabilities exceed assets. Despite 11.6% revenue growth to $297.2M, the company is burning cash with -$45.7M free cash flow and cannot achieve profitability with a -17.4% net margin. The company faces an existential solvency risk given negative equity, negative operating cash flow, and $146.1M in long-term debt against only $53.8M in cash.
Why Buy EOLS? Key Strengths
- Revenue growth of 11.6% YoY demonstrates market demand for products
- Strong gross margin of 66.3% indicates pricing power and product profitability at contribution level
- Current ratio of 1.90x suggests near-term liquidity to cover immediate obligations
EOLS Investment Risks to Consider
- Negative stockholders' equity of -$23.1M indicates technical insolvency and potential covenant violations
- Operating cash flow negative at -$42.3M with free cash flow of -$45.7M; company is depleting cash reserves unsustainably
- Operating loss of -$32.7M on $297.2M revenue indicates inability to convert gross profit to operational earnings despite revenue growth
- Long-term debt of $146.1M with only $53.8M cash and negative operating cash flow creates debt service risk
- Net loss of -$51.6M indicates cash burn accelerating beyond operating losses due to interest and other charges
Key Metrics to Watch
- Operating cash flow trajectory and path to positive FCF generation
- Stockholders' equity recovery and solvency status
- Ability to service $146.1M long-term debt with deteriorating cash position
- Operating margin improvement and timeline to profitability at EBIT level
- Cash burn rate and months of cash remaining at current depletion rates
EOLS Financial Metrics
💡 AI Analyst Insight
Evolus, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
EOLS Profitability Ratios
EOLS vs Healthcare Sector
How Evolus, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is EOLS Overvalued or Undervalued?
Based on fundamental analysis, Evolus, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
EOLS Balance Sheet & Liquidity
EOLS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Evolus, Inc.'s revenue has grown significantly by 198% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.08 indicates the company is currently unprofitable.
EOLS Growth Metrics (YoY)
EOLS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $61.1M | -$11.4M | $-0.24 |
| Q2 2025 | $66.9M | -$11.4M | $-0.18 |
| Q1 2025 | $59.3M | -$13.1M | $-0.22 |
| Q3 2024 | $50.0M | -$11.4M | $-0.30 |
| Q2 2024 | $49.3M | -$11.4M | $-0.18 |
| Q1 2024 | $41.7M | -$13.1M | $-0.22 |
| Q3 2023 | $33.9M | -$14.8M | $-0.30 |
| Q2 2023 | $37.2M | -$14.8M | $-0.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
EOLS Capital Allocation
EOLS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Evolus, Inc. (CIK: 0001570562)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EOLS
What is the AI rating for EOLS?
Evolus, Inc. (EOLS) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are EOLS's key strengths?
Claude: Revenue growth of 11.6% YoY demonstrates market demand for products. Strong gross margin of 66.3% indicates pricing power and product profitability at contribution level.
What are the risks of investing in EOLS?
Claude: Negative stockholders' equity of -$23.1M indicates technical insolvency and potential covenant violations. Operating cash flow negative at -$42.3M with free cash flow of -$45.7M; company is depleting cash reserves unsustainably.
What is EOLS's revenue and growth?
Evolus, Inc. reported revenue of $297.2M.
Does EOLS pay dividends?
Evolus, Inc. does not currently pay dividends.
Where can I find EOLS SEC filings?
Official SEC filings for Evolus, Inc. (CIK: 0001570562) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EOLS's EPS?
Evolus, Inc. has a diluted EPS of $-0.80.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EOLS a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Evolus, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EOLS stock overvalued or undervalued?
Valuation metrics for EOLS: ROE of N/A (sector avg: 15%), net margin of -17.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EOLS stock in 2026?
Our dual AI analysis gives Evolus, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EOLS's free cash flow?
Evolus, Inc.'s operating cash flow is $-42.3M, with capital expenditures of $3.4M. FCF margin is -15.4%.
How does EOLS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -17.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.90 (avg: 2).